Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Xavier University Of Louisiana currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and are being reviewed in 2 distinct art units. This distribution indicates that each pending matter is being handled by a different examiner in a separate technical group, rather than being clustered together. This suggests that the university's current pharmaceutical-related filings are technically distinct from one another.
The busiest examiner, BAUER, BRIANNA LEE, is responsible for 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, the workload is evenly divided between the involved officials. The involvement of 2 distinct art units for only 2 actions confirms that the prosecution is not concentrated in a single department. This spread across different examiners and art units may result in different prosecution timelines and outcomes for the university's pending applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18347724 | PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES | DEKARSKE, MADELINE MCGUIRE | 13d |
| 18891013 | SULFONATED AND PHOSPHORYLATED AROMATIC MOLECULES | BAUER, BRIANNA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18347724 | PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES | DEKARSKE, MADELINE MCGUIRE | 13d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891013 | SULFONATED AND PHOSPHORYLATED AROMATIC MOLECULES | BAUER, BRIANNA LEE | 1623 | §103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18347724 | PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103 | Final Rejection | 13d | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXavier University Of Louisiana has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brianna Lee Bauer has the most, with 1 of Xavier University Of Louisiana's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
